Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product for its advanced T cell therapies.
Quiver AI Summary
Autolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, was awarded the 2026 Prix Galien UK Award for Best Biotechnology Product by the Galien Foundation. This prestigious recognition, chosen by a committee of UK healthcare experts, acknowledges Autolus's commitment to translating pioneering scientific research into treatment options for patients. Dr. Martin Pule, the company's founder and Chief Scientific Officer, expressed gratitude for the award, highlighting the dedication of the team to patient care. Autolus is known for its development and delivery of T cell therapies for cancer and autoimmune diseases, boasting both a marketed therapy and a pipeline of candidates.
Potential Positives
- Autolus Therapeutics was awarded the prestigious 2026 Prix Galien UK Award for Best Biotechnology Product, highlighting its significant contributions to the biopharmaceutical field.
- This recognition from the Galien Foundation elevates the company's reputation within the healthcare community, potentially attracting investment and partnerships.
- The award underscores the successful translation of pioneering scientific research into practical treatment options, which may enhance investor and stakeholder confidence in the company's mission and products.
Potential Negatives
- None
FAQ
What award did Autolus Therapeutics win in 2026?
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product.
Who presented the Prix Galien UK Award to Autolus?
The award was presented by the Galien Foundation, which recognizes excellence in scientific innovation.
What is the mission of the Galien Foundation?
The Galien Foundation aims to foster and reward scientific innovation to improve human health.
Who is Dr. Martin Pule?
Dr. Martin Pule is the Founder and Chief Scientific Officer of Autolus Therapeutics and a clinical senior lecturer at UCL.
What types of therapies does Autolus develop?
Autolus develops next-generation programmed T cell therapies for cancer and autoimmune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AUTL Hedge Fund Activity
We have seen 36 institutional investors add shares of $AUTL stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MAK CAPITAL ONE LLC added 3,616,144 shares (+12.1%) to their portfolio in Q1 2026, for an estimated $4,990,278
- DEEP TRACK CAPITAL, LP removed 2,568,613 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,111,539
- BLACKROCK, INC. removed 2,205,093 shares (-59.8%) from their portfolio in Q1 2026, for an estimated $3,043,028
- ACADIAN ASSET MANAGEMENT LLC removed 1,776,520 shares (-98.5%) from their portfolio in Q1 2026, for an estimated $2,451,597
- AFFINITY ASSET ADVISORS, LLC removed 1,750,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,482,500
- ARMISTICE CAPITAL, LLC removed 1,700,000 shares (-9.7%) from their portfolio in Q1 2026, for an estimated $2,346,000
- ATLE FUND MANAGEMENT AB removed 1,169,634 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,614,094
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AUTL Analyst Ratings
Wall Street analysts have issued reports on $AUTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/12/2026
To track analyst ratings and price targets for $AUTL, check out Quiver Quantitative's $AUTL forecast page.
$AUTL Price Targets
Multiple analysts have issued price targets for $AUTL recently. We have seen 3 analysts offer price targets for $AUTL in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $10.0 on 05/14/2026
- Gil Blum from Needham set a target price of $10.0 on 04/09/2026
- Salim Syed from Mizuho set a target price of $10.0 on 03/31/2026
Full Release
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare.
“We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with University College London, to translate pioneering scientific research into new treatment options for patients in need. As a clinician, it is tremendously rewarding to see this vision become a reality. This award reflects the dedication of our teams, whose work is driven every day by a shared commitment to patients,” said Dr. Martin Pule, Founder and Chief Scientific Officer of Autolus, Clinical Senior Lecturer in the Department of Haematology at the UCL Cancer Institute, and Honorary Consultant in Haematology at University College London Hospital.
About The Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit
www.autolus.com
.
Contact:
Amanda Cray
Executive Director, Investor Relations & External Communications
+1 617-967-0207
[email protected]
